MARKETS
Analyst Actions

UBS Initiates Coverage On Twist Bioscience with Neutral Rating, Announces Price Target of $144

Sep 9, 2026 · 09:26 AM ET· updated 21h ago

UBS analyst Doug Schenkel initiates coverage on Twist Bioscience (NASDAQ:TWST) with a Neutral rating and announces Price Target of $144.

Share
Why It Matters

A big bank's analyst started watching Twist Bioscience and thinks it's worth around $144 per share, but isn't saying it's a great buy or a bad buy right now. When an expert starts paying attention to a company, it's worth noticing what they think, even if they're unsure about which way things will go.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.